Home / Health / EU Faces Injectable Schizophrenia Med Shortage
EU Faces Injectable Schizophrenia Med Shortage
27 Aug
Summary
- An injectable medicine for schizophrenia is facing shortages in the EU.
- Manufacturing issues at Greek contract firm Pharmathen are causing the shortage.
- The European Medicines Agency has no estimated end date for the supply issue.
The European Medicines Agency (EMA) has announced a shortage of an injectable medication crucial for treating schizophrenia across various EU member states. This scarcity stems from manufacturing disruptions experienced by Pharmathen International, a contract drug manufacturer based in Greece. The drug in question, paliperidone palmitate, is utilized for adults with schizophrenia whose conditions have been stabilized.
Several pharmaceutical companies, including Advanz Pharma and Biogaran, are affected by this supply issue. The EMA emphasized that the shortage is not linked to any quality defects or safety concerns regarding the medication itself.
As of the announcement, there is no projected end date for the shortage. Consequently, healthcare providers are being advised to explore alternative treatment options for patients. The EMA is actively collaborating with the marketing companies to mitigate the impact of this ongoing supply disruption.
